# SURFACE ANTIGENS OF HUMAN MYELOID PROGENITOR CELLS

> **NIH NIH R01** · DANA-FARBER CANCER INST · 1992 · $239,969

## Abstract

Granulocytes and moncytes are derived from a small population of
bone marrow progenitor cells which can be assayed in vitro by
their ability to form colonies of myeloid cells in semisolid
medium (colonyforming unit, CFUGM).  This colony formation
requires the presence of specific glyocoproteins termed colony
stimulating factors (CSF), produced by activated T cells and
monocytes.  CFUGM are present in low frequency in bone
marrow, and it has been very difficult to isolate these cells.  As a
result, very little is known about the events which regulate
proliferation and differentiation of these critical cells.

The longterm objectives of this project are to understand the
mechanisms which regulate CFUGM.  An important step in this
process is the development of techniques to purify these rare
cells.  Using a series of monoclonal antibodies developed in our
laboratory, we have developed a technique to enrich CFUGM
approximately 100 fold from normal bone marrow.  These purified
CFUGM have been used to:  1) develop a sensitive and specific
assay for CSF activity, 2) immunize mice to produce new
progenitor cell antibodies, 3) directly investigate the role of
HLADR surface antigens in the regulation of myelopoiesis, and
4) investigate the effects of cloned lines of human natural killer
cells on CFUGM.

In the continuation of this project, it is proposed to use purified
progenitor cells to assist in the screening for monoclonal
antibodies to the major growth factor of CFU-GM, G,-CSF; to
generate monoclonal antibodies to the GMCSF receptor using an
antiidiotype approach, and to initiate investigation of the early
transmembrane events (calcium flux, membrane potential
changes) induced in immature myeloid cells by GM-CSF and a
variety of other humoral regulators of myelopoiesis.  It is
anticipated that an improved knowledge of the mechanisms of
regulation of normal stem cells may also be ultimately useful in
understanding the abnormal regulation of myelopoiesis in
disorders such as AML.

## Key facts

- **NIH application ID:** 3173671
- **Project number:** 5R01CA036167-09
- **Recipient organization:** DANA-FARBER CANCER INST
- **SAM.gov UEI:** DPMGH9MG1X67
- **Principal Investigator:** JAMES DOUGLAS GRIFFIN
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 1992
- **Award amount:** $239,969
- **Award type:** 5
- **Project period:** 1984-03-01 → 1995-02-28

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/3173671

## Citation

> US National Institutes of Health, RePORTER application 3173671, SURFACE ANTIGENS OF HUMAN MYELOID PROGENITOR CELLS (5R01CA036167-09). Retrieved via MORVS 2026-10-25 from https://api.morvs.ai/grant/nih/3173671. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*